| Bioactivity | Guanabenz is an orally active α-2-adrenoceptor agonist. Guanabenz has antihypertensive effect and antiparasitic activity. Guanabenz interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz also is used for the research of high blood pressure[1][2][3]. |
| Invitro | Guanabenz (0.5-50 μM, 24 h) is treated with increasing concentrations for 24 hours not affect cell viability[1].Guanabenz (0.5-50 μM, 24 h) alone not affects the UPR targets, neither on mRNA or protein level nor the phosphorylation status of eIF2a. Guanabenz also not induces GADD34 or the constitutively active form CReP[1].Guanabenz (0.5-50 μM, 24 h) alone not induces ER stress in neonatal rat cardiomyocytes[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Guanabenz (5 mg/kg/day; i.p.; for 3 weeks) can reproducibly reduce brain cyst burden[2].Guanabenz (5 mg /kg/d, i.p., oral; 10 mg/kg/d, gavage; for 3 weeks) reverses Toxoplasma-induced hyperactivity in latently infected mice[2].Guanabenz (100 and 320 μg/kg and 1 mg/kg, i.v., over a period of 5 min at intervals of 40 min) reduces sympathetic outflow, heart rate and blood pressure in debuffered cats[3]. Animal Model: |
| Name | Guanabenz |
| CAS | 5051-62-7 |
| Formula | C8H8Cl2N4 |
| Molar Mass | 231.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Christiane Neuber, et al. Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes. PLoS One. 2014 Jun 3;9(6):e98893. [2]. Jennifer Martynowicz, et al. Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation. mBio. 2019 Apr 30;10(2):e00381-19. [3]. T Baum, et al. Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol. 1976 May;37(1):31-44. |